Why America’s Latest Commercial Gene Therapy Could Be a Big Money-Maker
The FDA has approved its second CAR-T cell therapy. This kind of treatment, which reprograms the DNA of a patient's T immune cells so that they attack cancer, has shown huge early success in trials and is widely anticipated to change the way many variants of the disease are dealt with in the future.
The lucky recipient of the new license to sell is Kite Pharma, and the therapy, called Yescarta, has been developed to treat specific types of the blood cancer non-Hodgkin's lymphoma. It's particularly heartening news for the pharmaceutical firm Gilead Sciences, which put up a cool $11.9 billion to acquire Kite Pharma in August.
Second place is sometimes said to be the first loser. That would seem especially so here, given that the first treatment to be approved, earlier this year, was Novartis's Kymriah—another CAR-T therapy that targets a kind of childhood blood cancer, acute lymphoblastic leukemia.
But consider this: even though both therapies treat blood cancer, Novartis's can theoretically treat around 600 people a year, while Kite's could benefit as many as 7,500. At $373,000 a time for a treatment of Yescarta, that could prove very lucrative indeed.
Keep Reading
Most Popular
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.